Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data

Diaz-Redondo, T; Lavado-Valenzuela, R; Jimenez, B; Pascual, T; Galvez, F; Falcon, A; Alamo, MD; Morales, C; Amerigo, M; Pascual, J; Sanchez-Munoz, A; Gonzalez-Guerrero, M; Vicioso, L; Laborda, A; Ortega, MV; Perez, L; Fernandez-Martinez, A; Chic, N; Jerez, JM; Alvarez, M; Prat, A; Ribelles, N; Alba, E – 2019